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This  was  the  third  meeting  on  pharmacogenetics  and 
pharmacogenomics organized by the European Science 
Foundation  and  University  of  Barcelona.  The  meeting 
was chaired by Laurent Becquemont (Université Paris-
Sud,  France),  with  Ann  Daly  (University  of  Newcastle, 
UK) as co-chair. It was attended by more than 100 people 
and covered a wide range of topics, including genome 
variability, pharmacogenomics of adverse drug reactions, 
cardiovascular diseases, transplantation and personalized 
cancer  treatment.  In  addition,  informative  sessions  on 
current knowledge of technology, methodology, applica-
tion of pharmacogenetics in drug companies and regu-
latory agencies complemented the interesting and varied 
program of the conference. There was a strong emphasis 
on the application of pharmacogenetics in routine clinical 
practice, which was discussed in length at the end of each 
plenary session with good contributions from all partici-
pants. A friendly atmosphere encouraged even the young-
est researchers to express their opinions in formal discus-
sion as well as in informal after-session conver  sation.
Patrice  Jaillon  (Hôpital  Saint  Antoine,  Paris,  France) 
provided an overview of the contribution of pharmaco-
genetics  to  clinical  pharmacology.  He  emphasized  that 
the personalized medicine era is already upon us and, in 
some clinical specialties, such as cancer medicine, pre-
treatment genetic testing is required in order to prescribe 
effective and safe drugs. A list of drugs for which genetic 
testing  is  required  is  available  from  several  websites 
(http://www.fda.gov/Drugs/ScienceResearch/
ResearchAreas/Pharmacogenetics/ucm083378.htm; 
http://www.ema.europa.eu/).
Becquemont  discussed  an  important  issue  of  study 
design in clinical pharmacogenetics. Most of the findings 
so far have been based on candidate gene approaches and 
only  a  few  randomized  controlled  trials  have  been 
conducted.  One  example  is  the  PREDICT1  study 
conducted in Australia to establish the effectiveness of 
prospective screening for the human leukocyte antigen 
variant  HLA-B*5701  to  prevent  the  hypersensitivity 
reaction to abacavir, which is used to treat HIV infection.
The  recent  expansion  of  genome-wide  association 
studies  (GWASs)  was  discussed  by  Matt  Nelson 
(GlaxoSmithKline,  Research  Triangle  Park,  NC,  USA). 
Study design, quality control of genotype and individual 
sample data, together with full reporting of ethnicity, are 
crucial components for correct interpretation of genome-
wide  analyses.  Conducting  both  appropriate  follow-up 
and replication in an independent cohort is necessary to 
validate associations found through an unbiased GWAS 
approach.
Pharmacogenetics of adverse drug reactions
The  importance  of  GWASs  was  stressed  throughout 
several talks in the Pharmacogenomics of Adverse Drug 
Reactions session. Daly provided an overview of drug-
induced liver injury (DILI) and presented two genome-
wide  studies  on  penicillin-induced  DILI.  Flucloxacillin 
(an antibiotic) has been found to be associated with the 
HLA-B*5701 allele (with a high odds ratio of 80), whereas 
DRB1*1501 (HLA class II, beta chain) seems to be the 
most important marker for DILI induced by co-amoxiclav 
(an  antibiotic).  It  is  apparent  that  the  associations 
between different HLA alleles and DILI are drug-specific. 
A  further  example  confirms  this  hypothesis; 
hepatotoxicity induced by lumiracoxib, a selective COX-2 
inhibitor  (non-steroidal  anti-inflammatory  drug),  has 
recently been associated with the DQA1*0102(HLA class 
II, alpha chain) allele. Despite these striking associations 
in terms of statis  tical significance (P-values < 3.5 × 10-35), 
the clinical utility of genetic markers for predicting liver 
toxicity is very limited. The negative predictive value of 
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1,  but  given  the  low  prevalence  of  DILI  (7  ×  10-5),  its 
positive  predictive  value  is  low  (0.0009),  therefore 
preventing its use as a predictive marker for DILI. The 
use of genetic testing as a diagnostic tool, rather than as a 
predictive marker, was also discussed.
Ana Alfirevic (University of Liverpool, UK) discussed 
drug-induced hypersensitivity reactions and HLA asso-
cia  tions. Considerable progress has been made in deter-
mining the genetic factors responsible for carbamazepine 
(a drug to treat epilepsy)-induced maculopapular exan-
thema (a skin reaction) and drug-induced hypersensitivity 
reactions with systemic symptoms, but clinical applica-
tion of HLA typing in Caucasian populations is not ready 
to  be  translated  into  routine  medical  practice.  Further 
effort  to  standardize  phenotype  and  identify  affected 
individuals through international collaboration has been 
initiated recently with the help of the Serious Adverse 
Events Consortium (http://www.saeconsortium.org/). The 
International Consortium on Drug Hypersensitivity and 
the  SAE  Phenotype  Standardization  Program  are  two 
initiatives  that  will  undoubtedly  help  researchers  to 
achieve better results through the collection of diverse 
patient cohorts and integrated genomic support.
Several other adverse drug reactions, including statin-
induced myopathy, were discussed at the meeting. Mikko 
Niemi (University of Helsinki, Finland) discussed statin-
induced  myopathy  in  relation  to  polymorphisms  in 
transporter  genes.  All  statins  are  substrates  for  the 
organic anion-transporting polypeptide 1B1 (OATP1B1), 
but the effects of the  SLCO1B1 (Solute carrier organic 
anion  transporter  family  member  1B1)  gene  poly  mor-
phisms differ greatly depending on which statin has been 
used.  Most  statins  are  also  substrates  for  efflux  trans-
porters  and  it  has  been  proposed  that  ABCG2  (ATP-
binding  cassette  sub-family  G  member  2)  may  have 
potential clinical value to guide and increase the safety of 
statin therapy.
Personalized cancer treatment
Pierre Laurent-Puig (INSERM, Université Paris V, France) 
discussed  the  individualization  of  epidermal  growth 
factor receptor (EGFR)-targeted therapy in patients with 
colorectal cancer. KRAS (V-Ki-ras2 Kirsten rat sarcoma 
viral  oncogene  homolog)  mutations  are  the  major 
determinant of response to anti-EGFR antibody therapy; 
however, in the population of cancer patients with wild-
type  KRAS  tumors,  other  mutations  have  a  significant 
role,  including  the  Val600Phe  mutation  in  BRAF,  a 
principal  downstream  effector  of  KRAS.  Interestingly, 
tumors with wild-type KRAS and BRAF and increased 
EGFR gene copy number have a high response rate (80%). 
These findings could help clinicians in selecting which 
colorectal cancer patients should be treated surgically.
Hiltrud Brauch (Margarete Fischer-Bosch Institut für 
Klinische  Pharmacologie  (IKP),  Stuttgart,  Germany) 
showed new developments in the pharmacogenetics of 
cytochrome P450 2D6 (CYP2D6) and tamoxifen outcome 
in early breast cancer and confirmed a strong relationship 
between a patient’s capacity to metabolize tamoxifen and 
treatment  outcome.  A  stratification  of  endocrine 
treatment based on CYP2D6 genotype has the potential 
to  reduce  breast  cancer  recurrence  and  mortality. 
Mathias  Schwab  (University  of  Tübingen  and  IKP, 
Stuttgart,  Germany)  discussed  the  individualization  of 
thiopurine  methyltransferase  therapy  (used  to  treat 
cancer) and stressed the need for integrative approaches 
that will include microarrays, genome-wide association 
data, systems biology and regulatory epigenetics.
Pharmacogenetics of cardiovascular diseases
In the Cardiovascular Disease session, Celine Verstuyft 
(Université Bicêtre, Le Kremlin-Bicêtre, France) presented 
the pharmacogenetics of clopidogrel (an antithrombotic 
drug). In the French Registry of Acute ST-Elevation and 
Non-ST-Elevation  Myocardial  Infarction  (FAST-MI) 
study it was shown that patients on clopidogrel carrying 
the  CYP2C19  loss-of-function  allele  had  an  increased 
risk  of  cardiovascular  events  when  undergoing  percu-
taneous coronary intervention. Prasugrel could be con-
sidered  as  an  alternative  as  it  did  not  show  these 
deleterious effects, but it was more toxic. Therefore, the 
clinical implications of these findings are still very much 
the subject of debate.
Mia  Wadelius  (Uppsala  University,  Uppsala,  Sweden) 
and one of us (AH-M-vdZ) discussed pharmacogenetic 
interactions  between  coumarins  (anticoagulant  drugs) 
and  VKORC1  (Vitamin  K  epoxide  reductase  complex 
subunit 1) and the cytochrome P450 gene CYP2C9. These 
genes have been shown to be important in both candidate 
gene studies and in GWASs. In Europe, the clinical utility 
of genotyping before starting therapy with a coumarin 
(warfarin,  acenocoumarol  or  phenprocoumon)  will  be 
studied in the European pharmacogenetics of anti  coagu-
lant therapy (EU-PACT) trial. Martin Fromm (University 
of  Erlangen,  Germany)  showed  that  drug  transporters 
(such  as  SLCO1B1  (Solute  carrier  organic  anion  trans-
porter  family  member  1B1))  and  organic  cation  trans-
porters (for example SLC22A1/A2 (Solute carrier family 
22 member 1/member 2)) might have a role in the efficacy 
of oral hypoglycemic agents.
Felix Frueh (Medco Health Solutions, Bethesda, MD, 
USA) explained the implementation of pharmacogenetics 
by Medco Health Solutions. If patients are prescribed a 
certain  drug  (for  example,  warfarin)  their  general 
practitioner will be contacted by telephone. If the general 
practitioner agrees with performing a pharmacogenetic 
test (67%) the patient will be contacted to be informed 
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whether the medication should be adjusted. If the patient 
agrees to use the test (82%), the test will be sent to the 
patient.  Finally,  the  test  will  be  sent  to  the  Medco 
laboratory, and, if necessary, the general practitioner can 
be advised to recommend changes to the medication.
Pharmacogenomics of organ transplantation
In the session on pharmacogenomics of organ trans  plan-
tation, Eric Thervet (Université Paris Descartes, France) 
presented  the  Tacrolimus  in  Renal  Transplantation 
Individualization  Through  Pharmacogenetic  (TacTic) 
study.  In  this  study  tacrolimus,  an  immunosuppressive 
drug used to prevent rejection in organ transplantation, 
was dosed according to CYP3A5 genotype in one arm of 
the study, and in the usual daily dose in the second arm. 
The primary outcome of the study (fewer dose modifi-
cations) was significantly different between the two arms. 
However,  there  was  no  difference  in  clinically  relevant 
endpoints. Ron van Schaik (Erasmus University, Rotter-
dam, the Netherlands) presented the pharmacogenetics 
of mycophenolic acid, an immunosuppressive drug used 
to prevent rejection in organ transplantation. Two genes, 
UGT1A9  (UDP-glucuronosyltransferase  1  family  poly-
peptide A9) and SLCO1B3 (Solute carrier organic anion 
transporter family member 1B3), have been suggested to 
influence  the  efficacy  of  organ  rejection  prevention. 
However,  there  is  not  enough  evidence  for  clinical 
implementation.  Evelyne  Jacqz-Aigrain  (INSERM, 
Hôpital  Robert  Debré,  Paris,  France)  talked  about  the 
pharmacogenetics  of  immunosuppressants  in  pediatric 
organ transplantation. She emphasized the importance of 
specific research in children; 28% of the world’s popu-
lation is under 18 years of age. Given the differences in 
pharmacokinetics  in  children  compared  with  the  adult 
population, it is important to conduct pharmacogenetic 
studies  in  children,  and  these  studies  should  be 
performed in different age groups.
Pharmacogenetics: hope or hype?
Ingolf  Cascorbi  (Christian  Albrechts  University,  Kiel, 
Germany)  delivered  the  final  talk  of  the  conference  in 
which  he  discussed  whether  pharmacogenetics  was  a 
‘hype or hope’. He presented an overview of examples of 
pharmacogenetic utility that were considered during the 
conference.  He  added  that  the  US  Food  and  Drug 
Administration  now  requires  genetic  testing  before 
starting  therapy  with  abacavir  and  carbamazepine  (in 
patients  of  Han  Chinese  or  Thai  origin)  and  also 
recommends testing before starting warfarin, irinotecan 
(a drug used in cancer) and azathioprine (an immuno-
suppressive drug) therapy. Furthermore, there is a long 
list  of  drugs  used  in  cancer  therapy  for  which  a 
pharmacogenetic test is required (for example, imatinib, 
nilotinib,  dasatinib,  trastuzumab,  cetuximab,  erlotinib 
and  gefitinib).  These  examples  show  that  pharmaco-
genetics is becoming more common in clinical practice. 
New developments in genotyping technologies, including 
next generation sequencing and the role of epigenetics, 
will move the field of pharmacogenetics forward.
We can conclude that pharmacogenetics is not hype. 
Pharmacogenetics already has a role in clinical practice 
and we believe that it will have an even more prominent 
role in personalizing pharmacotherapy in the future.
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